SEARCH

SEARCH BY CITATION

References

  • Beckett, A.H. & Rowland, M. (1965). Urinary excretion of methylamphetamine in man. Nature, Lond., 206, 12601261.
  • Birkmayer, W., Reiderer, P., Ambrozi, L. & Youdim, M.B.H. (1977). Implications of combined treatment with ‘Madopar’ and L-deprenyl in Parkinson's disease. Lancet, i, 439443.
  • Caldwell, J. (1976). The metabolism of amphetamines in mammals. Drug Metab. Revs., 5, 219280.
  • Cavanaugh, J.H., Griffith, J.D. & Oates, J.A.(1970). Effect of amphetamine on the pressor response to tyramine: Formation of p-hydroxynorephedrine from amphetamine in man. Clin. Pharmac. Ther., 11, 656664.
  • Durden, D.A., Philips, S.R. & Boulton, A.A. (1976). Identification and distribution of benzylamine in tissue extracts isolated from rats pretreated with pargyline. Biochem. Pharmac., 25, 858859.
  • Edwards, D.J. & Blau, K. (1973). Phenylethylamines in brain and liver of rats with experimentally induced phenylketonuria-like characteristics. Biochem. J., 132, 95100.
  • Elsworth, J.D., Glover, V., Reynolds, G.P., Sandler, M., Lees, A.J., Phuapradit, P., Shaw, K.M., Stern, G.M. & Kumar, P. (1978). Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the ‘cheese effect’. Psychopharmacology, 57, 3338.
  • Glover, V., Sandler, M., Owen, F. & Riley, G.J.(1977). Dopamine is a monoamine oxidase B substrate in man. Nature, Lond., 265, 8081.
  • Innes, I.R. & Nickerson, M. (1977). Norepinephrine, epinephrine and the sympathomimetic amines. In: The Pharmacological Basis of Therapeutics, ed. Goodman, L.S. & Gilman, A. pp. 477513.New York: Macmillan.
  • Kety, S.S. (1959). Biochemical theories of schizophrenia. Science, 129, 15281532.
  • Knoll, J. (1976). Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In Monoamine Oxidase and its Inhibition, ed. Wolstenholme, G.E.W. & Knight, J. pp. 135161, Amsterdam: Elsevier.
  • Lees, A.J., Shaw, K.M., Kohout, L.J., Stern, G.M., Elsworth, J.D., Sandler, M. & Youdim, M.B.H. (1977). Deprenyl in Parkinson's disease. Lancet, ii, 791796.
  • Magyar, K., Vizi, E.S., Ecsery, Z. & Knoll, J. (1967). Comparative pharmacological analysis of the optical isomers of phenyl-isopropylmethyl-propinylamine (E-250). Acta Physiol. Acad. Sci. Hung., 32, 377387.
  • Mendlewicz, J. & Youdim, M.B.H. (1978). The potentiation of the antidepressant properties of 5-hydroxytryptophan by deprenil. J. Neural Transmiss (in press).
  • Parkes, J.D., Tarsy, D., Marsden, C.D., Bovill, K.T., Phipps, J.A., Rose, P. & Asselman, P. (1975). Amphetamines in the treatment of Parkinson's disease. J. Neurol. Neurosurg. Psychiat., 38, 232237.
  • Simpson, L.L. (1978). Evidence that deprenyl, a type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine. Biochem. Pharmac., 27, 15911595.
  • Stern, G.M., Lees, A J. & Sandler, M. (1978). Deprenyl in Parkinson's disease. J. Neural Transmiss. in press.
  • Varga, E. & Tringer, L. (1967). Clinical trial of a new type of promptly acting psychoenergetic agent (phenyl-isopropylmethyl-propinylamine-HCl, E-250). Acta Med. Acad. Sci. Hung., 23, 289295.